Search results
Researchers reported an increase in BMD in the spine and hip with significantly fewer new vertebral fractures in patients using teriparatide versus alendronate in those at high risk for fracture; there was no significant difference in the two groups in the incidence of nonvertebral fractures. 96
13 lip 2020 · Osteoporosis, Postmenopausal / drug therapy* Osteoporosis, Postmenopausal / prevention & control* Osteoporotic Fractures / prevention & control
Bisphosphonates (BPs) are a commonly used class of drugs for the treatment of bone disorders. An extensive review of BPs with their clinical efficacy and safety profile is unavailable. This study aimed to review the available literature on BPs, ...
29 wrz 2023 · Background. Bisphosphonate medications are routinely prescribed for the treatment of osteoporosis, based on evidence that, correctly taken, they can improve bone strength and lead to a reduction in the risk of fragility fractures [1, 2].
5 lis 2019 · Alendronate is an option for maintaining or increasing bone mass, whereas risedronate is preferred in men with osteoporosis. [1] Off-Label Uses. Alendronate is used as an off-label medication for the below-mentioned conditions.
1 lut 2018 · Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including compliance and persistence).
17 maj 2021 · In this multicenter prospective, observational, postauthorization safety study conducted in Italy and Spain, postmenopausal women (PMW) with osteoporosis (naïve to bisphosphonates) were treated weekly with a buffered soluble alendronate 70 mg effervescent (ALN‐EFF) tablet (Binosto®) and followed for 12 ± 3 months.
